<![CDATA[Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer]]>

Data ReadoutpositivePositive

AI Analysis

Summary

Secondary analysis of the DEPROMP trial demonstrates that multimodal MRI- and PSMA PET/CT-guided prostate biopsy has low morbidity, with 94.8% of biopsy-naive men experiencing no adverse events immediately after the procedure.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

Secondary analysis of DEPROMP trial showed 94.8% of biopsy-naive men had no adverse events immediately after multimodal MRI- and PSMA PET/CT-guided prostate biopsy

Importance:5/10

Sentiment:

0.60

prostate cancerbiopsyMRIPSMA PET/CTDEPROMP trialsafety

Related Companies

$GTHP

Read the original article

Published by Cancer Network on September 29, 2026 3:00 PM

Read Original